By Fineline Cube 
Swiss giant Roche AG (SWX: ROG, OTCMKTS: RHHBY) announced last week a strategic partnership with US-based Broad Clinical Labs, a CLIA-licensed and CAP-accredited subsidiary of the Broad Institute. The collaboration aims to develop and pilot innovative applications of Roche’s next-generation sequencing (NGS) “Sequencing By Expansion (SBX)” technology. The goal is to enhance clinical genomics and biomedical discovery, positioning SBX as a routine, rapid, and scalable sequencing service for Broad Clinical Labs’ research community.
Collaboration Focus
The initial project under this partnership will apply SBX to advance triplet whole-genome sequencing studies involving critically ill newborns and their biological parents. This initiative seeks to establish whole-genome sequencing as a standard component of clinical care in neonatal intensive care units (NICUs). The aim is to enable precise and timely diagnoses, ultimately improving therapeutic outcomes for infants with suspected genetic disorders.-Fineline Info & Tech